Introduction {#s1}
============

Parkinson\'s disease (PD) is the second most common neurodegenerative disorder with an approximate incidence of 1:800--1,000 in subjects aged over 60 years old (Bekris et al., [@B16]; Lin and Farrer, [@B119]). PD is a progressive disorder that affects movement that is often diagnosed based on the presence of motor signs such as tremor, bradykinesia, muscle rigidity, and postural instability though in some PD patients, non-motor symptoms of anxiety, fatigue, depression, sleep disturbance, gastrointestinal, and sexual dysfunctions are also observed (Schneider and Obeso, [@B168]). As PD is an age-related disorder, it is more common in the elderly; however younger individuals may also be affected (Gasser et al., [@B64]) and these patients are usually known as early onset PD (EOPD) patients. The typical PD, or also known as late onset PD (LOPD), is defined for individuals more than 50 years old who exhibit PD signs and symptoms (Schrag and Schott, [@B169]). Some of EOPD patients show slower disease progression and worse disease outcomes in comparison to LOPD patients (Schrag et al., [@B170]; Inzelberg et al., [@B88]; Ferguson et al., [@B59]), implying that there could be biological differences that dictates the disease outcomes and also the age of onset of PD. There are some evidence that EOPD may be associated with some genetic alterations in the PD progression (Oki et al., [@B153]), yet the molecular mechanisms to differentiate the EOPD and LOPD progression remains unclear and requires further understanding.

Parkinson\'s disease (PD) is a multi-factorial disease involving interactions between environment and genetic factors (Farrer, [@B55]; Sellbach et al., [@B172]). Initially, PD is thought to be a sporadic disease due to environmental factors such as exposure to toxins namely, paraquat, 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP) or pesticides (Langston et al., [@B106]; Ascherio and Schwarzschild, [@B10]). However, in the past few decades, genetic inheritance has been also identified to be one of the causative factors that could contribute to PD progression (Gasser et al., [@B64]; Lin and Farrer, [@B119]). About 90% of PD cases are sporadic whereas \>10% of PD patients have a family history with the contribution of one or several genetic alterations (Klein and Westenberger, [@B102]; Ascherio and Schwarzschild, [@B10]). These genetic alterations in PD can be categorized into autosomal dominant (AD) and autosomal recessive (AR) of PD (Bekris et al., [@B16]; Klein and Westenberger, [@B102]). The AD form of PD is associated with alterations of the α-synuclein (*SNCA*) and leucine rich repeat kinase 2 (*LRRK2*) genes (Bekris et al., [@B16]; Klein and Westenberger, [@B102]) whereas the Parkin RBR E3 ubiquitin protein ligase (*PRKN)*, Parkinsonism associated deglycase (*PARK7*), PTEN induced putative kinase 1 (*PINK1*) and ATPase 13A2 (*ATP13A2*) genes are linked to the AR form of PD (Nuytemans et al., [@B151]; Heman-Ackah et al., [@B82]). Current effective treatments for both motor and non-motor symptoms in PD are available, yet the heterogeneous nature of this disease causes diverse clinical manifestations across the PD patients (Oertel and Schulz, [@B152]) reducing the effectiveness of those treatments. Moreover, the underlying mechanisms of PD are still poorly understood and the lack of effective approach to differentiate and identify the EOPD and LOPD patients also contribute to the complexity of PD management. Therefore, finding the early diagnostic approaches for EOPD and LOPD are essential for better disease management.

Biological markers, or biomarkers like proteins or other molecular elements which are expressed by cells and tissues can reflect the pathological processes underlying PD progression. The fact that these biomarkers can readily be found in body fluids, such as in blood, urine, or even in cerebrospinal fluid (CSF) (Gwinn et al., [@B74]) therefore they are the most suitable biomarkers which can accurately diagnose the disease and symptoms, as well as predicting the severity and progression. One such biomarker is microRNAs (miRNAs), in which the recent discovery of miRNAs involvement in PD has garnered interest especially their roles in disease progression (Serafin et al., [@B173]). miRNAs are single non-coding small RNAs (19--24 nucleotides), which are able to regulate gene expression by mRNA repression or mRNA cleavage (Bartel, [@B13]). Compared to other organs, there are more miRNAs expressed in the human brain, in which previous studies observed that the function of these brain miRNAs are not only restricted to cell fate determination (Meza-Sosa et al., [@B140]), but are also involved in neuroplasticity and neurobiological functions (Qiu et al., [@B159]; Batistela et al., [@B15]). Dysregulation of these miRNAs leads to mitochondrial dysfunction, altered mitochondrial dynamics, accumulation of fragmented mitochondria, oxidative stress, excitotoxicity, cell death and α-synuclein aggregation, thus subsequently causing neurodegeneration (Martin, [@B131]; Spano et al., [@B183]). Since a single miRNA can regulate different genes and a single target gene may also be regulated by multiple miRNAs (Qiu et al., [@B159]), this network regulation of miRNAs and their complementary target mRNAs may provide additional insights on the disease progression and possible new therapeutic approaches. Given these interests, this mini review aimed to discuss the role of PD related genes and their regulatory microRNAs to differentiate the early-onset (EOPD) and late-onset PD (LOPD). The applications and challenges of using these microRNAs as potential biomarkers are also discussed.

Early and late onset of parkinson disease {#s2}
=========================================

Within the PD patients, those who are below 50 years old when they first exhibited the PD symptoms are classified as EOPD, which is less common compared to LOPD, or typical PD (Schrag et al., [@B170]; Schrag and Schott, [@B169]). The mortality of EOPD is two times greater than typical PD cases (Schrag et al., [@B170]). EOPD patients experience a longer disease course, with slower disease progression and cognitive decline, yet some motor complications such as dyskinesia and dystonia have been observed to develop earlier than LOPD (Schrag et al., [@B170]; Inzelberg et al., [@B88]; Ferguson et al., [@B59]), consequently causing a significant impairment in the quality of life. In fact, a previous study showed that between EOPD and LOPD patients, the dopaminergic neurons (DA) loss is greater in the EOPD group (Fereshtehnejad et al., [@B58]), implying that there are differences in the underlying pathophysiology and molecular mechanisms. However, more definitive and confirmatory studies are needed to differentiate between these two subsets of PD patients for better management and personalized treatment.

Parkinson\'s disease (PD) symptoms are usually present when about 70--80% of the dopaminergic (DA) neurons are lost (Goldenberg, [@B68]). The neuropathological hallmark of PD is the deposition of the intracytoplasmic protein inclusions known as Lewy bodies (LB) that are composed of various molecules including α-synuclein (protein product of *SNCA* gene) aggregates, which is responsible for the loss of DA neurons in the midbrain of substantia nigra (Spillantini et al., [@B184]; Wakabayashi et al., [@B202]; Longhena et al., [@B120]). Currently, there is no test or examination that can be performed to diagnose PD at an early stage accurately. The standard approach for PD diagnosis is based on the patient\'s and family history, and on neurological examination to demonstrate the presence of the common signs and symptoms including bradykinesia, rigidity, and tremor (Massano and Bhatia, [@B134]). Magnetic resonance imaging has also been used as a tool to analyse for brain abnormalities in which multisystem atrophy, progressive supranuclear palsy or cortical degeneration were identified to differentiate between PD and atypical parkinsonism (Ba and Martin, [@B11]). However, the sensitivity for this MRI diagnosis was only around 60--80% (Kraft et al., [@B104]; Feng et al., [@B57]; Hwang et al., [@B86]) thus limiting its diagnostic value. Nevertheless, the confirmative diagnosis of PD can only be done through a neuropathological investigation by detecting the loss of DA neurons and the presence of LB and Lewy neurites in the brain (Braak et al., [@B19]; Massano and Bhatia, [@B134]).

There is currently no single genetic test to accurately identify those who are susceptible to PD. However, recent findings showed that some genetic markers can be used to diagnose EOPD. Genes such as *PRKN, PARK7, PINK1, LRRK2*, and Glucosylceramidase beta (*GBA*) have been consistently shown to be associated with age of onset in PD exclusively (Klein and Westenberger, [@B102]; Lin and Farrer, [@B119]). Several genetic mutations in *PRKN* have been associated with EOPD (Deng et al., [@B44]; Chen H. et al., [@B29]) in which the frequency of this gene mutations in the EOPD population is about 7.2--12.5% (Hardy et al., [@B77]). In fact, mutations in *PRKN* gene are the most common cause for EOPD that account for 50% of those EOPD patients (onset age \<25 years) and about 3--7% for EOPD patients (onset age = 30--45 years) (Lücking et al., [@B124]; Periquet et al., [@B157]). Thus, *PRKN* gene is likely to be the main player of genetic susceptibility in PD progression at a much earlier age. A more rare genetic association was observed for *PINK1* gene, in which the mutations in *PINK1* gene is responsible for about 2--4% of EOPD cases in Caucasians (Valente et al., [@B197]; Bonifati et al., [@B17]) and 4--9% in Asian populations (Li et al., [@B116]; Tan et al., [@B188]). Similarly, the mutations in *PARK7* are also rare in EOPD that represent about 1% of the total EOPD cases (Abou-Sleiman et al., [@B2]; Hague et al., [@B75]), yet the inheritance of these homozygous or heterozygous mutations of *PARK7* are almost 100% (Schulte and Gasser, [@B171]), therefore making *PARK7* gene as equally important as *PRKN* gene. On the other hand, *GBA* and *LRKK2* mutations are generally associated with typical PD with the late-onset symptoms, though severe mutations in *GBA* gene tended to be associated with much early age of the PD onset (Lesage et al., [@B112]). About 8% of the *LRRK2* mutation carriers were EOPD patients (Healy et al., [@B81]). Therefore, these genes may offer potential diagnostic values in predicting the EOPD and differentiate them from the typical late-onset PD. Nevertheless, these genetic mutations alone (DNA biomarker) may not be enough to differentiate EOPD from LOPD due to PD heterogeneity and their prevalence in the populations. Thus, a combination of these mutated genes as well other related genes and their respective regulatory microRNAs (stable RNA biomarker) should offer a better diagnostic option as they reflect the actual dysregulation of the cellular states and disease progression of EOPD; hence allowing for a sensitive genetic testing to differentiate EOPD from LOPD.

microRNA regulatory network in parkinson disease {#s3}
================================================

The microRNA regulatory network in PD has been discussed before, particularly in the potential of miRNAs as circulating biomarkers for the diagnosis and treatment of PD (dos Santos et al., [@B49]; Ma et al., [@B126]; Marques et al., [@B129]; Mushtaq et al., [@B145]; Batistela et al., [@B15]), in PD progression (Heman-Ackah et al., [@B82]) as well as in the oxidative stress pathway (Qiu et al., [@B160]; Xie and Chen, [@B216]). However, none of these discussions emphasis on the potential of these miRNAs to differentiate the EOPD from LOPD. From 2011 till now, there were few studies that investigated the miRNAs profile in the EOPD patients and compared them to LOPD patients in which lots of LOPD studies did not include the EOPD comparison (Table [1](#T1){ref-type="table"}). Among these identified miRNAs, few of them showed a promise as a potential biomarker for EOPD especially, when their validated targets/genes are involved in PD progression (Figure [1](#F1){ref-type="fig"}). Among them, miR-34b and miR-34c have been shown to be decreased in the brain tissues in both EOPD and LOPD patients (Miñones-Moyano et al., [@B141]). Since miR-34b and miR-34c are shown to target multiple genes in PD including *PRKN* and *PARK7* (Miñones-Moyano et al., [@B141]), *SNCA* (Kabaria et al., [@B97]), *MAPT* (Wu H. et al., [@B212]), these miRNAs are potentially useful to detect early dysregulation and onset of PD progression. Importantly, miR-331-5p is the only miRNAs that has been identified in plasma of EOPD patients exclusively, with its expression was increased in EOPD patients with no difference was observed in LOPD (Cardo et al., [@B24]). However, no validated targets/genes were identified for miR-331-5p particularly in PD progression, thus these would require further investigation. From these findings, they implied that the role of miRNAs in PD disease progression is significant and thus could also play a role in the determining the age-onset of PD symptoms. Therefore, the potential roles of these miRNAs and their target genes in differentiating EOPD from LOPD will be discussed below, particularly by looking at the various PD pathological events.

###### 

Summary of the altered microRNAs and their targeted genes in Parkinson Disease (PD) with a focus on EOPD and LOPD patients.

  **Diagnosis**   **Sources**                                      **miRNAs**       **miRNA expression in EOPD**   **miRNA expression in LOPD**   **Validated target genes associated with PD**
  --------------- ------------------------------------------------ ---------------- ------------------------------ ------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  EOPD            Whole Blood (Margis et al., [@B128])             miR-1            Reduced                        NS                             *BDNF* (Brandenburger et al., [@B20]; Varendi et al., [@B199])
                                                                   miR-22           Reduced                        NS                             *BDNF* (Muiños-Gimeno et al., [@B144])
                                                                   miR-29a          Reduced                        Reduced                        --
                  Brain Tissues (Miñones-Moyano et al., [@B141])   miR-34b,c        Reduced                        Reduced                        *PRKN* and *PARK7* (Miñones-Moyano et al., [@B141]), *SNCA* (Kabaria et al., [@B97]), *MAPT* (Wu H. et al., [@B212])
                  Plasma (Cardo et al., [@B24])                    miR-331-5p       Increased                      NS                             --
                  Serum (Dong et al., [@B47])                      miR-141          Reduced                        Reduced                        *KEAP1* (Shi et al., [@B177]; Wang et al., [@B205]; Cheng et al., [@B31])
                                                                   miR-146b-5p      Reduced                        Reduced                        --
                                                                   miR-193a-3p      Reduced                        Reduced                        --
                                                                   miR-214          Reduced                        Reduced                        *SNCA* (Wang Z. H. et al., [@B210])
  LOPD            Whole Blood (Serafin et al., [@B174])            miR-103a         NC                             Increased                      --
                                                                   miR-29a          NC                             Increased                      --
                                                                   miR-30b          NC                             Increased                      --
                  Whole Blood (Yilmaz et al., [@B222])             miR-3143         NC                             Reduced                        --
                                                                   miR-335-3p       NC                             Reduced                        --
                                                                   miR-4671-3p      NC                             Reduced                        --
                                                                   miR-561-3p       NC                             Reduced                        --
                                                                   miR-579-3p       NC                             Reduced                        --
                  Brain tissues                                    miR-34b,c        Reduced                        Reduced                        *PRKN* and *PARK7* (Miñones-Moyano et al., [@B141]), *SNCA* (Kabaria et al., [@B97]), *MAPT* (Wu H. et al., [@B212])
                  Brain tissue (Liao et al., [@B117])              miR-181a,b,c,d   NC                             Reduced                        *PRKN* (Cheng et al., [@B32])
                                                                   miR-22           NC                             Reduced                        *BDNF* (Muiños-Gimeno et al., [@B144])
                                                                   miR-29a,b,c      NC                             Reduced                        --
                  Brain tissue (Alvarez-Erviti et al., [@B9])      miR-106a         NC                             Increased                      *HSPA8* (Alvarez-Erviti et al., [@B9])
                                                                   miR-21           NC                             Increased                      *LAMP2A* (Alvarez-Erviti et al., [@B9]; Su et al., [@B186]), *PPARA* (Fu et al., [@B62])
                                                                   miR-224          NC                             Increased                      *LAMP2A* (Alvarez-Erviti et al., [@B9]), NPAS4 (Choy et al., [@B35])
                                                                   miR-26b          NC                             Increased                      *HSPA8* (Alvarez-Erviti et al., [@B9]), *RB1* (Absalon et al., [@B3]), *BDNF* (Caputo et al., [@B23])
                                                                   miR-301b         NC                             Increased                      *HSPA8* (Alvarez-Erviti et al., [@B9])
                                                                   miR-373          NC                             Increased                      *LAMP2A* (Alvarez-Erviti et al., [@B9])
                  Brain tissue (Cho et al., [@B33])                miR-205          NC                             Reduced                        *LRRK2* (Cho et al., [@B33])
                  Brain tissue (Cardo et al., [@B25])              miR-135b         NC                             Reduced                        --
                                                                   miR-198          NC                             Reduced                        --
                                                                   miR-485-5p       NC                             Reduced                        --
                                                                   miR-548d         NC                             Increased                      --
                  Brain tissue (Hoss et al., [@B83])               Let-7i-3p/5p     NC                             Reduced                        --
                                                                   miR-10b-5p       NC                             Reduced                        BDNF (Varendi et al., [@B199])
                                                                   miR-1224         NC                             Reduced                        --
                                                                   miR-127-3p       NC                             Reduced                        --
                                                                   miR-127-5p       NC                             Increased                      *GBA* (Siebert et al., [@B179])
                                                                   miR-16-5p        NC                             Increased                      --
                                                                   miR-184          NC                             Reduced                        --
                                                                   miR-29a-3p       NC                             Increased                      --
                  Brain tissues (Tatura et al., [@B191])           miR-144          NC                             Increased                      --
                                                                   miR-145          NC                             Reduced                        --
                                                                   miR-199b         NC                             Increased                      --
                                                                   miR-221          NC                             Increased                      --
                                                                   miR-488          NC                             Increased                      --
                                                                   miR-543          NC                             Reduced                        --
                                                                   miR-544          NC                             Increased                      *PARK7* (Jin et al., [@B94])
                                                                   miR-7            NC                             Reduced                        *SNCA* (Junn et al., [@B95]; Doxakis, [@B50]),*NLRP3* (Zhou et al., [@B231]), *RELA* (Choi et al., [@B34]), *KEAP1* (Kabaria et al., [@B96]), *VDAC1* (Chaudhuri et al., [@B28])
                  Brain tissues (Wake et al., [@B203])             miR-225          NC                             Reduced                        --
                                                                   miR-236          NC                             Increased                      --
                                                                   miR-46           NC                             Increased                      --
                  CSF (Burgos et al., [@B22])                      Let-7g-3p        NC                             Increased                      --
                                                                   miR-1224-5p      NC                             Reduced                        --
                                                                   miR-127-3p       NC                             Reduced                        --
                                                                   miR-128          NC                             Reduced                        *CYP2D6* (Li et al., [@B114])
                                                                   miR-132-5p       NC                             Reduced                        --
                                                                   miR-19a,b        NC                             Increased                      --
                                                                   miR-212-3p       NC                             Reduced                        --
                                                                   miR-370          NC                             Reduced                        --
                                                                   miR-409-3p       NC                             Reduced                        --
                                                                   miR-4448         NC                             Reduced                        --
                                                                   miR-485-5p       NC                             Reduced                        --
                                                                   miR-873-3p       NC                             Reduced                        --
                  CSF (Gui et al., [@B71])                         Let-7g-3p        NC                             Increased                      --
                                                                   miR-1            NC                             Reduced                        *BDNF* (Brandenburger et al., [@B20]; Varendi et al., [@B199])
                                                                   miR-103a         NC                             Increased                      --
                                                                   miR-10a-5p       NC                             Increased                      --
                                                                   miR-119a         NC                             Reduced                        --
                                                                   miR-126          NC                             Reduced                        --
                                                                   miR-127-3p       NC                             Increased                      --
                                                                   miR-132-5p       NC                             Increased                      --
                                                                   miR-136-3p       NC                             Increased                      --
                                                                   miR-151          NC                             Reduced                        --
                                                                   miR-153          NC                             Increased                      *SNCA* (Doxakis, [@B50]; Kim et al., [@B101]; Lim and Song, [@B118]), *NFE2L2* (Narasimhan et al., [@B146]; Yang W. et al., [@B219])
                                                                   miR-16-2         NC                             Increased                      --
                                                                   miR-19b-3p       NC                             Reduced                        --
                                                                   miR-22           NC                             Reduced                        *BDNF* (Muiños-Gimeno et al., [@B144])
                                                                   miR-26a          NC                             Increased                      *BDNF* (Caputo et al., [@B23])
                                                                   miR-28           NC                             Reduced                        *NFE2L2* (Yang et al., [@B218])
                                                                   miR-29a,c        NC                             Reduced                        --
                                                                   miR-301a         NC                             Reduced                        --
                                                                   miR-30b          NC                             Increased                      --
                                                                   miR-331-5p       NC                             Increased                      --
                                                                   miR-370          NC                             Increased                      --
                                                                   miR-374          NC                             Reduced                        --
                                                                   miR-409-3p       NC                             Increased                      --
                                                                   miR-433          NC                             Increased                      *FGF20* (Wang et al., [@B204])
                                                                   miR-485-5p       NC                             Increased                      --
                                                                   miR-873-3p       NC                             Increased                      --
                  CSF (Soreq et al., [@B182])                      miR-1249         NC                             Increased                      --
                                                                   miR-1274b        NC                             Increased                      --
                                                                   miR-150          NC                             Increased                      --
                                                                   miR-16           NC                             Reduced                        *HSPA8* (Zhang and Cheng, [@B228])
                                                                   miR-18b          NC                             Increased                      --
                                                                   miR-199b         NC                             Increased                      --
                                                                   miR-20a          NC                             Increased                      --
                                                                   miR-21           NC                             Increased                      *LAMP2A* (Alvarez-Erviti et al., [@B9]; Su et al., [@B186])
                                                                   miR-320a,b       NC                             Reduced                        *HSPA8* (Li G. et al., [@B113])
                                                                   miR-378c         NC                             Increased                      --
                                                                   miR-4293         NC                             Increased                      --
                                                                   miR-671          NC                             Increased                      --
                                                                   miR-769          NC                             Reduced                        --
                                                                   miR-92b          NC                             Reduced                        --
                  Plasma (Khoo et al., [@B100])                    miR-222          NC                             Reduced                        --
                                                                   miR-505          NC                             Reduced                        --
                                                                   miR-626          NC                             Reduced                        --
                  Serum (Botta-Orfila et al., [@B18])              miR-19b          NC                             Reduced                        --
                                                                   miR-29a,c        NC                             Reduced                        --
                  Serum (Zhao et al., [@B229])                     miR-133b         NC                             Reduced                        *RHOA* (Lu X. C. et al., [@B122]; Niu et al., [@B150])
                  Serum (Bai et al., [@B12])                       miR-29a,b,c      NC                             Reduced                        --
                  Serum (Ma et al., [@B126])                       miR-146a         NC                             Reduced                        --
                                                                   miR-214          NC                             Reduced                        *SNCA* (Wang Z. H. et al., [@B210])
                                                                   miR-221          NC                             Reduced                        --
                                                                   miR-29c          NC                             Reduced                        --
                  Serum (Burgos et al., [@B22])                    miR-1294         NC                             Reduced                        --
                                                                   miR-16-2-3p      NC                             Reduced                        --
                                                                   miR-30a,e        NC                             Increased                      *BDNF* (Mellios et al., [@B138])
                                                                   miR-338-3p       NC                             Increased                      --
                  Serum (Vallelunga et al., [@B198])               miR-148b         NC                             Reduced                        --
                                                                   miR-223          NC                             Increased                      *NLRP3* (Yang Z. et al., [@B221])
                                                                   miR-24           NC                             Increased                      --
                                                                   miR-30c          NC                             Reduced                        --
                                                                   miR-324-3p       NC                             Increased                      --
                  Serum (Ding et al., [@B46])                      miR-15b          NC                             Reduced                        --
                                                                   miR-181a         NC                             Reduced                        *PRKN* (Cheng et al., [@B32])
                                                                   miR-185          NC                             Reduced                        --
                                                                   miR-195          NC                             Increased                      *BDNF* (Mellios et al., [@B138])
                                                                   miR-221          NC                             Reduced                        --
                  PBMCs (Martins et al., [@B133])                  miR-126          NC                             Reduced                        --
                                                                   miR-126^\*^      NC                             Reduced                        \-
                                                                   miR-147          NC                             Reduced                        --
                                                                   miR-151-3p,5p    NC                             Reduced                        --
                                                                   miR-199a-3p,5p   NC                             Reduced                        --
                                                                   miR-199b         NC                             Reduced                        --
                                                                   miR-19b          NC                             Reduced                        --
                                                                   miR-26a          NC                             Reduced                        *BDNF* (Caputo et al., [@B23])
                                                                   miR-28-5p        NC                             Reduced                        --
                                                                   miR-29b,c        NC                             Reduced                        --
                                                                   miR-301a         NC                             Reduced                        --
                                                                   miR-30b,c        NC                             Reduced                        --
                                                                   miR-335          NC                             Reduced                        --
                                                                   miR-374a,b       NC                             Reduced                        --

*Summary of the significantly altered microRNAs expressions in EOPD and LOPD studies. All the validated targets/genes for these microRNAs are listed below only in a relation with PD progression or associated pathways where it is possible. EOPD, early-onset PD, LOPD, late-onset PD, NS, Not significant, NC, No comparison was made. Genes full names are in the [appendix](#SM1){ref-type="supplementary-material"}*.

![Illustrated regulatory network of altered microRNAs and their targeted genes in pathophysiology of Parkinson\'s disease. Altered microRNAs from EOPD and LOPD studies are significantly involved in the regulating various molecules in pathophysiological of PD, particularly in mitochondrial dysfunction, oxidative stress, neuro-inflammation, and toxic protein accumulation. Red-colored microRNAs are significantly altered in EOPD patients. Genes full names are in the [appendix](#SM1){ref-type="supplementary-material"}.](fnmol-10-00352-g0001){#F1}

MicroRNAs in mitochondrial dysregulation
----------------------------------------

One of the earliest events in PD pathophysiological processes is the mitochondrial dysregulation (Figure [1](#F1){ref-type="fig"}). Impairment in oxidative phosphorylation can result in dysregulation of the mitochondrial activity and energy metabolism thus can increase reactive-oxygen-species (ROS) production and oxidative stress, eventually lead to neurotoxicity and death (Dias et al., [@B45]; Hu and Wang, [@B84]). This is evident by the reduced of mitochondrial complex I activity observed in PD patients (Schapira et al., [@B167]) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), which is an important activator for mitochondrial genes, was decreased in PD patients (Zheng et al., [@B230]). In fact, experimental studies of using neurotoxin, MPTP (Kolata, [@B103]) and pesticides like rotenone (Perier et al., [@B156]) showed similar mitochondrial dysregulation thus, re-affirmed that damaged mitochondria as a key mechanism for DA neuronal impairment. Several keys regulators have been identified in mitochondrial dysregulation in PD, particularly the PRKN and PINK1 interaction (Deas et al., [@B42]). Previous studies have shown that PINK1 is responsible to detect mitochondrial damage and recruits PRKN enzyme to ubiquitinate the damaged mitochondria (Matsuda et al., [@B136]; Narendra et al., [@B147]; Vives-Bauza et al., [@B200]). This ubiquitination tagging will allow the mitophagy to occur and remove the damaged mitochondria (Deas et al., [@B42]) from the cytoplasm, therefore preventing the parkinsonism to develop. Moreover, PRKN regulates the Zinc finger protein 746 (also known as PARIS) (Shin et al., [@B178]), which is a transcriptional repressor of *PGC1*α gene (Scarpulla, [@B166]). Dyregulation of *PGC1*α expression will affects energy metabolism and mitochondrial biogenesis (Wu et al., [@B214]). In the progression of PD due to nitrosative stress and ROS, suppression of *PRKN* gene expression resulted in an accumulation of ZNF746 in the cytosol (LaVoie et al., [@B107]). The formation of the ZNF746 complex selectively downregulates nuclear respiratory factor-1 that controls transcription of the mitochondrial biogenesis, consequently causes DA degeneration (Shin et al., [@B178]). Besides PRKN and PINK1, PARK7 or also known as protein deglycase (*DJ1*) can bind to mitochondrial complex I subunit, NDUFA4 and NADH dehydrogenase 1 and subsequently prevented PD progression via maintaining the complex 1 activity (Hayashi et al., [@B79]). Therefore, changes in these genes (*PRKN, PINK1*, and *PARK7*) expression and functions may therefore be indicators of mitochondrial damage and dysregulation that mark the initial progression of PD and neurodegeneration in the patients.

Several studies have implied that miRNAs play crucial role as biomarkers and a therapeutic agent to prevent mitochondrial dysfunction in PD (Figure [1](#F1){ref-type="fig"}). One such is miR-34b and miR-34c that co-regulate both PARK7 and PRKN, as evidently by the suppression of both miRNAs resulted in a significant reduction in the expression of *PARK7* and *PRKN* (Miñones-Moyano et al., [@B141]). Previous study involving PD patients at different stages of the disease, showed that there was a downregulation of 40--65% expression of miR-34b and miR-34c in the brain, both in EOPD and LOPD patients (Miñones-Moyano et al., [@B141]; Table [1](#T1){ref-type="table"}). The findings implied that both of these miRNAs may play a role in pathogenesis of PD rather than a consequence of PD progression, since those EOPD patients did not received any drug treatment yet (Miñones-Moyano et al., [@B141]). In addition, suppression of miR-34b/c expressions in the differentiated SH-SY5Y cells also resulted in a moderate reduction of the cell viability, with the presence of altered mitochondrial function, oxidative stress and also the reduction of the total cellular ATP content in the cells (Ma et al., [@B125]), confirming that the suppression of miR-34b/c is an indicator of early progression of PD due to mitochondrial damages in the patients, consistent with the reduced expressions of miR-34b/c in both EOPD and LOPD studies (Table [1](#T1){ref-type="table"}). Other miRNAs is miR-181a that is highly expressed in the brain (Miska et al., [@B142]) and can directly regulate *PRKN* gene expression (Cheng et al., [@B32]). miR-181a expression found to be reduced in the brain (Liao et al., [@B117]) and serum (Ding et al., [@B46]) of LOPD patients. Overexpression of miR-181a suppressed *PRKN* expression and partially inhibited the removal of dysfunctional mitochondria by mitophagy (Cheng et al., [@B32]), thus subsequently leads to disruption in energy maintenance and mitochondrial quality control. Importantly, introduction of PRKN back into the cells eliminated those negative effects of miR-181a (Cheng et al., [@B32]), implying that an increase of miR-181a expression may reflect the onset of mitochondrial dysregulation consistent with the suppression of PRKN. However, in PD patients, none of the EOPD studies showed changes in miR-181a expression whereas in LOPD patients, miR-181a expression was reduced (Table [1](#T1){ref-type="table"}). Another miRNAs is miR-544 that was increased in the brain tissues of LOPD patients (Tatura et al., [@B191]) and can directly bind to 3′UTR of PARK7 mRNA region to suppress *PARK7* expression (Jin et al., [@B94]), however, whether miR-544 is implicated in PD progression remains unknown. Another miRNA is miR-7 that regulates *SNCA* expression and α-synuclein level (Junn et al., [@B95]; Doxakis, [@B51]). In experimental model of PD, α-synuclein can inhibit mitochondrial complex I activity and causes mitochondrial damage (Martin et al., [@B132]). This is also showed by an overexpression of pathogenic α-synuclein, A53T/A30P that caused mitochondrial fragmentation via dynamin-like 120 kDa protein, thus implies that α-synuclein also play a role in mitochondrial dysregulation. Moreover, miR-7 also regulates mitochondrial permeability via voltage-dependent anion channel 1 (VDAC1) (Chaudhuri et al., [@B28]), though how this gene is involved in PD progression particularly in mitochondrial dysregulation would require further studies. Intriguingly, a study of the LRRK2 mice model has identified three differentially expressed miRNAs (miR-16, miR-15a, and miR-21) in *LRRK2*-knockout mice compared to wildtype mice (Dorval et al., [@B48]). These miRNAs were predicted to affect mitochondrial dysfunction and apoptosis following dysregulation of miR-16/15 expression (Cimmino et al., [@B36]; Nishi et al., [@B149]). Interestingly, in this study (Dorval et al., [@B48]), miR-103 was found to be down-regulated in transgenic mice expressing PD-associated *LRRK2* R1441G mutation when compared to wildtype mice, yet no information of the direct regulation or predicted site of miR-103 in *LRRK2* gene was observed. This miR-103 dysregulation may suggest that there are underlying mechanisms of miR-103 regulation of *LRRK2* gene which may be implicated in PD progression. Previous study showed that elevated level of LRRK2 protein can induce mitochondrial fragmentation via dynamin-like protein (Wang et al., [@B208]). Nevertheless, some of these miRNAs were altered in the EOPD patients thus may offer diagnostic potential to differentiate EOPD and LOPD, though more information are needed as the comparison for EOPD patients are lacking in those previous studies (Table [1](#T1){ref-type="table"}).

MicroRNAs in α-synuclein regulation and protein control system
--------------------------------------------------------------

SNCA gene encodes the α-synuclein protein and among the important genes that are associated with PD in general, *SNCA* gene is well-recognized as the main player in PD pathogenesis, in which mutations or rearrangements of *SNCA* gene are found in those with autosomal dominant PD (Thomas et al., [@B193]; Klein and Westenberger, [@B102]). Genome-wide association studies have demonstrated that *SNCA* gene is significantly associated with PD in multiple populations (Simón-Sánchez et al., [@B180]; Hamza and Payami, [@B76]; Tan et al., [@B189]; Guo et al., [@B72]; Foo et al., [@B60]). There is evidence of the *SNCA* gene susceptibility alleles affecting the expression and plasma level of *SNCA* (Bekris et al., [@B16]; Mata et al., [@B135]), thus reaffirming the important role of SNCA in PD susceptibility. Structurally, α-synuclein is a protein with a natively unfolded monomer which forms β-sheet-rich soluble oligomers (Outeiro et al., [@B155]; Stefanis, [@B185]). Mutated α-synuclein protein has a tendency to aggregate and forms a mature fibril which in turn increases the inclination to form LB (Dawson et al., [@B41]; Stefanis, [@B185]). Moreover, the accumulation of transmissible α-synuclein aggregates in a cell can be transferable to another cell thus causing a cumulative risk of the LB spreading across the neurons, and eventually inducing major cells deaths (Dauer and Przedborski, [@B40]; Recasens et al., [@B162]). Intriguingly, higher levels of normal non-mutated α-synuclein protein also increases α-synuclein protein aggregation and LB formation in PD patients (Singleton et al., [@B181]), suggesting that slight changes in *SNCA* gene expression or α-synuclein protein level will trigger PD progression regardless of the mutational status of *SNCA* gene or α-synuclein protein. Therefore, it is important that *SNCA* gene expression is tightly regulated in the brain and hence, miRNA regulatory network of *SNCA* gene expression may play important roles in triggering the PD progression and can be the potential biomarkers to identify EOPD.

Several microRNAs are shown to be able to regulate *SNCA* gene expression (Figure [1](#F1){ref-type="fig"}; Recasens et al., [@B163]), and few of them are significantly been altered in EOPD patients (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). Previous study of miRNA expression profiling in brain tissues of PD patients revealed that decreased expression of miR-34b and miR-34c in amygdala region of the brain can be detected in EOPD patients even without any pre-motor symptoms, though similar miR-34b/c reduction was also seen in LOPD patients (Miñones-Moyano et al., [@B141]). miR-34b/c have been shown to regulate *SNCA* gene expression and α-synuclein protein as well as neuronal toxicity, due to miR-34b, and miR-34c can directly bind to 3′UTR of *SNCA* mRNA (Kabaria et al., [@B97]). Inhibition of miR-34b and miR-34c expression in SH-SY5Y neuronal cells caused an increase of α-synuclein protein levels and promoted α-synuclein aggregation (Kabaria et al., [@B97]). Importantly, in this study (Kabaria et al., [@B97]), a single-nucleotide polymorphism (SNP) in *SNCA* gene, rs10024743 which causes a change of U to G nucleotide at the 3′UTR of *SNCA* mRNA, inhibited the miR-34b binding to *SNCA* mRNA. These findings suggest that the role of genetic susceptibility in *SNCA* gene can alter the outcome of miRNA regulation and subsequently contribute to PD. Besides that, a previous study that used four miRNAs as serum biomarkers to identify EOPD have found that miR-214 was reduced in both EOPD and LOPD patients, when compared to normal controls, yet its expression did not differ between EOPD and LOPD groups (Table [1](#T1){ref-type="table"}; Dong et al., [@B47]). Like miR-34b/c, miR-214 has also can regulate *SNCA* gene expression and α-synuclein protein (Wang Z. H. et al., [@B210]). In fact, miR-214 regulatory action of *SNCA* mRNA expression is linked with the mechanisms of neuroprotection in Resveratrol, a potential therapeutic drug treatment in PD (Albani et al., [@B6]), therefore implying that this miRNA may have been the molecular regulator of interest in the mechanism of the resveratrol-therapy in PD. Another is miR-7 that is highly expressed in the neurons and can also bind directly to the 3′UTR of *SNCA* mRNA (Junn et al., [@B95]; Doxakis, [@B51]). miR-7 controls the expression of *SNCA* gene by decreasing the mRNA stability rather than modifying the protein translation rate (Ma et al., [@B125]). Suppression of *SNCA* gene expression by miR-7 will inhibit proteasome impairment and protect the cells from oxidative stress (Junn et al., [@B95]). In fact, this neuroprotective of miR-7 against α-synuclein aggregates has been replicated in various experimental conditions to induce cell death, including due to impaired mitochondrial activity (Choi et al., [@B34]; Fragkouli and Doxakis, [@B61]) or genetic mutation of A53T in SNCA gene (Fan et al., [@B54]; Zhou et al., [@B231]). Despite these neuroprotective actions of miR-7, only one LOPD study actually showed the differentially expressed miR-7 in human samples (Table [1](#T1){ref-type="table"}), in which its expression was reduced in LOPD patients at the region of gyri cinguli (Tatura et al., [@B191]). This is particularly important as these findings may imply that miR-7 regulation of α-synuclein is more complicated than the normal direct-mRNA binding and suppression, seen in *in vitro* cells or experimental animals or it may suggest that miR-7 regulates multiple target genes thus its expression is highly maintained or there are other underlying regulators. This is partially supported by a previous study that showed *SNCA* gene expression can be synergistically suppressed by combination of miR-7 and miR-153 action (Doxakis, [@B50]; Kim et al., [@B101]; Fragkouli and Doxakis, [@B61]; Lim and Song, [@B118]), in which endogenous α-synuclein protein level was 30--40% reduced (Doxakis, [@B50]). Like miR-7, miR-153 is also highly expressed in the brain and can directly bind to the 3′UTR of *SNCA* mRNA (Doxakis, [@B50]; Kim et al., [@B101]; Lim and Song, [@B118]). This combined regulatory action of miR-7 and miR-153 may therefore explain the lack of alteration in miR-7 and miR-153 expression in PD patients. However, none of these microRNAs are specific enough to differentiate the EOPD from LOPD patients as both miR-34b and c were also altered in LOPD patients (Table [1](#T1){ref-type="table"}). The fact that no association of *SNCA* gene was observed in the susceptibility of EOPD (Martin et al., [@B130]; Schulte and Gasser, [@B171]) and this fate is also shared by their regulatory miRNAs, these may imply that measuring *SNCA* gene expression may not suitable for early diagnosis of PD. Nevertheless, some these miRNAs were significantly altered in EOPD patients even with no symptoms observed therefore they offer some potential as biomarkers to differentiate EOPD. Further information is needed to explore and identify more regulatory biomarkers in EOPD, as the current studies were limited in numbers (Table [1](#T1){ref-type="table"}).

The role of α-synuclein in the brain is currently unclear thus investigating on other miRNAs that indirectly regulate *SNCA* gene expression and α-synuclein protein may provide additional information. Intriguingly, lysosomal-associated membrane protein 2A (LAMP2A) and heat shock protein family A member 8 (HSPA8) can also regulate α-synuclein protein level via chaperone-mediated autophagy (Vogiatzi et al., [@B201]; Alvarez-Erviti et al., [@B8]). Thus, few miRNAs like miR-21, miR-224, miR-379, and miR-373 that regulate *LAMP2A* expression (Alvarez-Erviti et al., [@B9]; Su et al., [@B186]) and miR-26b, miR-106a, miR-301b, miR-16-1, and miR-320a that regulate *HSPA8* expression (Alvarez-Erviti et al., [@B9]; Li G. et al., [@B113]; Zhang and Cheng, [@B228]) could also be considered as potential biomarkers in PD progression, and these were consistent with their altered expressions in LOPD studies (Table [1](#T1){ref-type="table"}). Similar indirect regulation of *SNCA* gene expression by other miRNAs has also been observed, including miR-133b via RAS homolog family member A (RHOA) (Lu X. C. et al., [@B122]; Niu et al., [@B150]), miR-433 via fibroblast growth factor 20 (FGF20) (Wang et al., [@B204]), miR-128 (Decressac et al., [@B43]), and miR-155 (Thome et al., [@B194]), which resulted in changes of *SNCA* expression and protein level. Given that some of these microRNAs were found to be significantly altered in LOPD studies (Table [1](#T1){ref-type="table"}), thus this neuroprotection of miRNAs network in regulating α-synuclein protein level may therefore potentially be used as biomarker for PD progression, though their roles in differentiating EOPD would requires more investigations, as there was no comparison of EOPD in those previous LOPD studies (Table [1](#T1){ref-type="table"}).

Besides α-synuclein, other proteins in the brain have been identified to cause PD, with evidence of dysregulation of protein quality and control system. One such is the *LRRK2* gene that is a candidate gene in autosomal dominant PD (Lesage and Brice, [@B111]; Kett and Dauer, [@B99]). LRRK2 is primarily involved in the regulation of neurite maintenance and neuronal survival (MacLeod et al., [@B127]). Previous study was done in rats to investigate the relationship between *LRRK2* and α-synuclein found that the increase of striatal α-synuclein protein level also increased the mRNA level of *LRRK2* (Gehrke et al., [@B66]). In fact, regardless of the mutational status of *LRRK2* gene in PD patients with or without LB pathology, \~20--100% of α-synuclein-positive LB also contained high levels of *LRRK2* mRNA (Daher et al., [@B39]), which suggests that *LRRK2* and α-synuclein have synergetic effects (Guerreiro et al., [@B70]). Besides that, a soluble microtubule-associated protein tau (MAPT) that modulates the stability of axonal microtubules (Greggio et al., [@B69]) had been shown to play a role in the PD progression by interacting with LRRK2. Analogous to the amyloid formation by α-synuclein, MAPT can also form aggregates which deposit into neurofibrillary tangles (Li J.-Q. et al., [@B115]). There was a significant elevation of phosphorylated MAPT at Thr181 and Ser396 locations in *LRRK2*-overexpressing cells (Kawakami et al., [@B98]). This increase in MAPT phosphorylation was reduced by *LRRK2* knockdown only at position Thr181, suggesting that LRRK2 positively regulates MAPT phosphorylation at the Thr181 location only. While at the Ser396 location, the MAPT phosphorylation was induced by LRRK2 protein due to unknown mechanism (Li J.-Q. et al., [@B115]). Nevertheless, these phosphorylated MAPT proteins are implicated in PD progression, especially in the role of toxic protein accumulation. Consequently, overexpression of *LRRK2* expression led to reduced locomotor activity and loss of DA (Saha et al., [@B164]; Serafin et al., [@B173]), suggesting that LRRK2 plays an important role in conferring early susceptibility to PD, particularly in controlling the protein levels. Like LRRK2, GBA protein which is a lysosomal membrane protein that cleaves the glycosylceramide (Winfield et al., [@B211]) also plays a role in protein control system. The loss of lysosomal function arising from dysregulation of GBA will lead to cell toxicity due to accumulation of toxic proteins that can contribute to PD progression (Goker-Alpan et al., [@B67]). A pilot study on the Jewish population, found that N370S, L444P, T369M, and R469H mutations in the *GBA* gene were associated with PD (Clark et al., [@B37]), though these findings have not been replicated in other populations. Further studies are needed to confirm the role of GBA in progression of PD, particularly in EOPD, as this gene is currently been associated with LOPD susceptibility (Martin et al., [@B130]; Schulte and Gasser, [@B171]). Similar to GBA, ubiquitin-proteasome system (UPS) that comprises of three enzymes, E1, E2 and E3 also been implicated in PD (McNaught et al., [@B137]). This is supported by the role of PRKN, which has E3 ligase function and loss of PRKN activity caused DA neuron loss without formation of LB (Cook et al., [@B38]). However, unlike GBA, several mutations in *PRKN* gene have been associated with EOPD (Deng et al., [@B44]; Chen H. et al., [@B29]), which exclusively indicates that PRKN plays important roles in early events of PD, particularly in EOPD progression.

Several miRNAs have been shown to regulate *LRRK2* and *GBA* expression (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). A previous study of PD patients compared to healthy controls showed that the circulating levels of miR-335-3p, miR-561-3p, and miR-579-3p were associated with PD susceptibility, with miR-561-3p having the strongest association (Saha et al., [@B164]). In fact, in comparison between LOPD patients and normal controls also revealed that miR-335-3p, miR-561-3p, and miR-579-3p were reduced in whole blood (Yilmaz et al., [@B222]) and PBMCs (Martins et al., [@B133]) samples. However, these miRNAs were only predicted to target *LRRK2* gene (Saha et al., [@B164]), with no evidence of direct regulation. The only confirmed regulatory miRNAs for LRRK2 is miR-205 that can directly bind to 3′UTR region of *LRRK2* mRNA and this miRNA was down-regulated in LOPD patients (Cho et al., [@B33]). Interestingly, miR-205 prevented neurite outgrowth defects in neurons expressing PD-related *LRRK2* R1441G mutants (Cho et al., [@B33]), thus suggesting that this miRNA can protect the progression of PD due to LRRK2 genetic susceptibility, which may be a potential therapeutic approach in *LRRK2* PD patients. Another study that compared LRRK2-mutated PD patients to healthy controls (Botta-Orfila et al., [@B18]), has identified three differentially expressed miRNAs (miR-29c, miR-29a, and miR-19a) in LRRK2-mutated PD patients. Among these miRNAs, two of them (miR-29c and miR-29a) were also found to be differentially expressed in idiopathic PD. As both *LRRK2* PD and idiopathic PD shared similar molecular pathways dysregulation (Botta-Orfila et al., [@B18]), it implied that the *LRRK2* gene may play a role in early onset of the disease. As for the *MAPT* gene, miR-34c have been shown to directly regulate MAPT phosphorylation and expression yet this was only shown in gastric cancer (Wu H. et al., [@B212]). Indirect regulation of MAPT phosphorylation was also identified, in which miR-26b regulates RBI (Absalon et al., [@B3]) and miR-138 regulates RARA/GSK-3β pathway (Wang X. et al., [@B207]), that resulted in suppression of MAPT phosphorylation. As for *GBA* gene, miR-16--5p, and miR-195--5p are predicted to regulate *GBA* expression, yet only miR-127-5p was shown to reduce GBA activity and protein synthesis (Siebert et al., [@B179]), and may contribute to neuronal cell toxicity and PD progression. This is in agreement with previous findings as miR-127-5p expression was increased in the brain tissue of LOPD patients (Hoss et al., [@B83]), consistent with the findings that GBA gene is altered in LOPD patients and certain mutations in *GBA* were tended to be associated with EOPD (Martin et al., [@B130]; Schulte and Gasser, [@B171]). However, to what extend that *LRRK2* and *GBA* genes and their regulatory miRNAs can be used to differentiate and identify EOPD in the patients is still unclear, but they surely are reasonable biomarkers for LOPD patients.

MicroRNAs in oxidative stress
-----------------------------

Another implicated pathway in PD is the oxidative stress that plays important role in disease progression including (1) increasing DNA and mitochondrial DNA mutation, (2) dysregulation of protein homeostasis/degradation, (3) regulation of dopamine release, and (4) disruption of cellular self-defense, protection and survival (Dias et al., [@B45]). Experimental study of PD showed that increased ROS production and alteration of antioxidants were observed (Cassarino et al., [@B26]). In fact, endogenous antioxidant, the nuclear factor erythroid 2-related factor 2 (NFE2L2) significantly translocate from the cytoplasm into the nucleus to activate antioxidant activity genes in PD (Ramsey et al., [@B161]). Usually, NFE2L2 is primarily been suppressed by Kelch-like ECH-associated protein 1 (KEAP1, a NFE2L2 sequester protein) in cytoplasm, but upon under oxidative stress, NFE2L2 activates the expression NADPH quinine oxidoreductase 1, heme oxygenase-1, superoxide dismutase, glutathione and many other antioxidant agents/proteins (Satoh et al., [@B165]; Zhang et al., [@B226]). Independent of KEAP1 regulation, *NFE2L2* expression can also be regulated by protein kinase C and glycogen synthase kinase 3 beta or epigenetic factors (Bryan et al., [@B21]). Importantly, *NFE2L2* gene and its genetic variants have been implicated as a possible marker for EOPD in Australian PD study (Todorovic et al., [@B196]), thus confirming the role of oxidative stress in EOPD progression. Another important molecule in oxidative stress is PARK7 that can stabilize NFE2L2 and able to regulate superoxide dismutase 1 via interaction with ERK1/2-ELK1 pathway (Wang et al., [@B209]). Previous studies also showed that PARK7 also acts as an antioxidant (Taira et al., [@B187]) and as a redox-sensor protein to prevent α-synuclein protein aggregation (Abou-Sleiman et al., [@B2]; Shendelman et al., [@B176]). PARK7 is proposed to be involved in mitochondrial protection by directly inhibits 20S proteasome activity and recruits NADPH quinone oxidoreductase-1 to co-regulate 20S proteasome activity via stabilization of NFE2L2 (Moscovitz et al., [@B143]). Similarly to NFE2L2, hemochromatosis gene is also been considered as a potential biomarker for EOPD (Bartzokis et al., [@B14]), due to its role in iron metabolism and iron-redox balance in oxidative stress (Faucheux et al., [@B56]). However, recent studies did not find strong relationship of this gene variants, C282Y and H63D with PD in various populations (Aamodt et al., [@B1]; Duan et al., [@B52]; Xia et al., [@B215]), therefore may imply that the role of this hemochromatosis gene in PD may require further investigation.

Several microRNAs that were identified as biomarkers in PD patients are also implicated in oxidative stress via the genes above (Figure [1](#F1){ref-type="fig"}). One such is miR-153 that can directly regulates *NFE2L2* expression and overexpression of miR-153 led to increase of ROS production in the cells (Narasimhan et al., [@B146]; Yang W. et al., [@B219]). This is particularly relevant, as miR-153 expression was increased in CSF of LOPD patients (Gui et al., [@B71]), which indicates that there are dysregulation of oxidative stress and antioxidant system, consistent with miR-153 regulatory role on NFE2L2. Besides miR-153, miR-7 can also regulate NFE2L2 pathway via direct binding to 3′UTR of *KEAP1* mRNA (Kabaria et al., [@B96]). Similarly, miR-141 also regulates *KEAP1* expression (Shi et al., [@B177]; Wang et al., [@B205]; Cheng et al., [@B31]), whereas miR-28 directly regulates *NFE2L2* mRNA, independently of KEAP1 (Yang et al., [@B218]), but these relationships were only observed in other cell types. Aside from that, miR-494 was identified before can directly downregulate *PARK7* expression by binding to the 3′UTR of *PARK7* mRNA and overexpression of miR-494 reduced PARK7 protein levels and resulted in increased susceptibility of the neuron cells to oxidative stress (Xiong et al., [@B217]). Consequently, ROS production was increased when miR-494 is overexpressed in neuron cells, and this effect was diminished by an introduction of PARK7 into those miR-494 overexpressed cells (Xiong et al., [@B217]), confirming the negative regulation of *PARK7* expression by miR-494 that contributes to PD progression. However, expression of miR-494 was not changed in PD patients, regardless of EOPD or LOPD comparison (Table [1](#T1){ref-type="table"}).

MicroRNAs in neuro-inflammation
-------------------------------

In relation with oxidative stress, neuro-inflammation and immune response are also implicated as key players in the onset of disease progression for both sporadic and familial PD (Chao et al., [@B27]; Tiwari and Pal, [@B195]). In fact, previous studies showed that microglial-mediated inflammatory event happens at the early onset of PD (Ouchi et al., [@B154]; Iannaccone et al., [@B87]). In the brain, microglia are the major resident immune cells that provide innate immunity, together with astrocytes and oligodendrocytes (Taylor et al., [@B192]). Usually, microglia maintains the brain healthy environment with neurotrophic factors like brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 and interleukin 10 (Taylor et al., [@B192]). Though, the introduction of toxic pesticides or protein aggregates lead to activation of NFκB pathway (Lee, [@B109]) and increased neurotoxic factors like inflammatory cytokines (TNFα, tumor necrosis factor alpha, interleukins like IL-1b), chemokines (MCP-1 and CCL2), prostaglandins and pattern recognition receptors like toll-like-receptors and nod-like-receptor (NLRs) (Taylor et al., [@B192]). Subsequently, uncontrolled inflammation events lead to increase of ROS and oxidative stress and eventually neuronal damage (Taylor et al., [@B192]). The role of these cytokines and inflammatory factors in PD progression have been discussed recently (Tiwari and Pal, [@B195]). Among them, NLR family, pyrin domain-containing 1 (NLRP1), 3 (NLRP3) and 5 (NLRP5) are known to contribute to neuroinflammation and neuronal death (Meng et al., [@B139]; Lawana et al., [@B108]). Others like alpha-2 macroglobulin (A2M) protein, which is a major component of the brain innate immune system and has been linked with EOPD (Krüger et al., [@B105]). However, there are studies that shown an opposite relationship and no correlation between A2M and the age-onset of PD (Nicoletti et al., [@B148]; Tang et al., [@B190]; Guo et al., [@B73]). Taken together, these findings suggest that an active inflammatory process in the CNS of PD patients includes innate immune system.

Regulation of inflammatory initiators by microRNAs may provide beneficial outcomes in PD. This is evident by a study of intracerebral hemorrhage in mice revealed that miR-223 can reduce brain edema and inflammation by direct-inhibition of NLRP3 inflammasome (Yang Z. et al., [@B221]). As miR-223 expression was increased in LOPD patients (Vallelunga et al., [@B198]), this may indicate that the increase of miR-223 expression in late-stage was probably a negative feedback mechanism to control the neuroinflammation and possibly to reduce cell death in the late-onset of PD. Whereas, miR-7 that also regulates NLRP3 (Zhou et al., [@B231]) and proto-oncogene, NF-kB subunit/p65 protein (RELA) (Choi et al., [@B34]), its expression was reduced in the brain tissues of LOPD patients (Tatura et al., [@B191]) thus indicates a loss of miR-7 neuroprotection in PD progression. In a mice MPTP model of PD, an introduction of miR-7116 prevented TNF-α production and loss of DA neurons, due to miR-7116 can directly bind to TNF-α to inhibit its production (He et al., [@B80]). Even though, miR-7116 was not implicated with EOPD or LOPD studies (Table [1](#T1){ref-type="table"}), yet TNF-α itself can regulates other miRNAs that are known regulators for mitochondrial function and subsequently can contribute to oxidative stress and apoptosis (Prajapati et al., [@B158]). Thus, miR-7116 may play a greater role in the PD progression, especially in the early stage of inflammatory events. Intriguingly, in EOPD patients, both miR-1, and miR-22 expressions were reduced (Margis et al., [@B128]), and their common validated target/gene is BDNF (Muiños-Gimeno et al., [@B144]; Brandenburger et al., [@B20]; Varendi et al., [@B199]), which is known to increase dopaminergic neuroprotection (Fumagalli et al., [@B63]). Therefore, reduced of these microRNAs expression in those EOPD patients may therefore indicates that *BDNF* expression was up-regulated to promote early rescue of DA neurons, thus these miRNAs may potentially be the biomarkers to differentiate EOPD. Despite that, there are other microRNAs that also regulates *BDNF* expression, and some of them are been implicated both in EOPD and LOPD patients (Table [1](#T1){ref-type="table"}). Whether these miRNAs can be used to differentiate EOPD specifically enough is unknown and requires further investigations on their sensitivity and specificity.

MicroRNAs and others genes in parkinson disease
-----------------------------------------------

Other pathways than above have also been discussed in the progression of PD (Alonso-Navarro et al., [@B7]). One such is the drugs and xenobiotics detoxification mechanisms pathways, in which a mice MPTP model of PD study showed that a polymorphism in cytochrome P450 family two subfamily D member 6 (*CYP2D6*) caused susceptibility to PD (Jiménez-Jiménez et al., [@B93]). Following that, others have shown that some of these detoxification genes, *GSTM1, GSTT1*, and *NAT2* have been implicated in PD with controversial associations (Wang and Wang, [@B206]; Jiménez-Jiménez et al., [@B91]). Importantly, *CYP2D6* and *NAT2* genes have been shown exclusively to be associated with EOPD (Agúndez et al., [@B4]; Agundez et al., [@B5]), implying that these detoxification genes would have be suitable as EOPD biomarkers. Similar to that, genes that are involved in dopamine metabolism and transport (*DRD3, SLC6A3, MTHFR*), also showed to pose a risk for PD (Wu Y.-L. et al., [@B213]; Zhai et al., [@B225]; Hassan et al., [@B78]), with particularly, dopamine receptor D3 (*DRD3*) gene that has been implicated in EOPD patients (Hassan et al., [@B78]). Due to heterogeneity of PD, various other genes have also been associated with PD in one or two populations, including saitohin protein (Lu et al., [@B121]), vitamin D receptor (Gatto et al., [@B65]), semaphorin 5A (Yu et al., [@B224]), granulin (Chen Y. et al., [@B30]), histamine N-methyltransferase (*HNMT*) (Jiménez-Jiménez et al., [@B92]), Ras like without CAAX 2 (Lu Y. et al., [@B123]; Foo et al., [@B60]), syntaxin 1B, parkinson disease 16, *FGF20*, glycoprotein nmb (International Parkinson\'s Disease Genomics and Wellcome Trust Case Control, [@B89]), serine/threonine kinase 39 (Foo et al., [@B60]) and huntingtin interacting protein 1 related (*HIP1R*) (Yu et al., [@B223]) genes. Among these genes, *HNMT* and *HIP1R* genes have been found to be implicated with the age-onset of the disease, specifically for *HNMT* in EOPD (Yang X. et al., [@B220]) whereas *HIP1R* gene in LOPD (Yu et al., [@B223]). The roles of these genes in PD progression require further investigation, as some of these genes were only reported once in association, while others have controversial relationships with PD.

Among those miRNAs that been investigated in EOPD and LOPD patients, some of them were found to regulate *CYP2D6* and *DRD3* genes (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). One such is in the comparison between LOPD patients and normal controls, miR-128 expression in CSF samples was found to be reduced (Burgos et al., [@B22]) and miR-128 can directly bind to *CYP2D6* mRNA and suppression its expression (Li et al., [@B114]), which may indicates that *CYP2D6* expression was up-regulated in the LOPD patients, consistent with the needs of CYP2D6 to metabolize the neurotoxins in PD. Although Let-7d was no listed in the differentially expressed microRNAs in EOPD and LOPD studies (Table [1](#T1){ref-type="table"}), Let-7d was shown to directly regulate the expression of *DRD3* (Zhang et al., [@B227]), which is also a gene that have been associated with EOPD (Hassan et al., [@B78]). However, no validated and significant microRNA was found to regulate *HNMT* and *HIP1R* expression in brain specifically. Despite CYP2D6 gene was associated with EOPD (Agúndez et al., [@B4]; Agundez et al., [@B5]) yet, its regulatory miRNA was only found to be significant in LOPD studies. The reason for such discrepancies may due to the fact that those LOPD studies did not include a comparison to EOPD patients thus undermines the searching of those miRNAs as biomarkers in EOPD. Also, the possibility of indirect and underlying regulation of these microRNAs and validated targets/genes may also contribute to the inconsistencies. Nevertheless, these miRNAs and their target genes may offer potential diagnostic values in EOPD, as they are significantly altered in patients and some of their target genes are consistently been involved in PD progression, yet further investigations are required to validate such roles.

Challenges of using miRNA as biomarkers for diagnosis of EOPD {#s4}
=============================================================

miRNAs have an immense potential as biomarkers for the early diagnosis of PD as they are easily detectable in body fluids and a good number of them correlates with disease progression. Developing a technique to detect PD earlier has become important due to the burden of the disease in which most of the cases are detected when 70--80% of the dopaminergic neurons are lost (Goldenberg, [@B68]), thus reducing the efficiency of the treatment and recovery. The idea for an early diagnosis to prevent the neuro-degeneration by a simple blood sampling is enticing, and this would make the diagnosis of PD more efficient and economical (Khoo et al., [@B100]). Currently, the physicians diagnose PD by carefully taking the patient\'s neurological history and performing a thorough physical examination to detect for the symptoms and signs of PD (Jankovic, [@B90]). To date, the most accurate testing currently available for PD is to image the dopamine system and brain metabolism through specialized brain scanning, and these tests could only be performed in specialized imaging centers, therefore can be very expensive (Lees et al., [@B110]). Thus, using the miRNAs as blood biomarkers or CSF sampling give new strategy to improve the screening and diagnosis of PD. In fact, combination of the genetic mutation (DNA biomarker) together with regulatory miRNAs (stable RNA biomarker) in a screening panel could offer a better diagnostic approach, with an ability to differentiate the onset and progression of PD as well-determine their severity, hence a sensitive molecular testing.

One of the problems in identifying microRNAs as biomarkers for any disease is the inconsistency of expression between circulating microRNA and the tissue expression. There are a few explanations behind this situation. One reason is that changes in the concentrations of ubiquitous miRNAs causing or associated with the pathology of the disease can be limited and do not necessarily reflect their concentrations in the body fluids due to the small amount of miRNAs from the affected organ or tissues spilling into the circulatory system (Sheinerman and Umansky, [@B175]). Another reason is that the changes in miRNA expression are more prominent at the site of the pathological hallmark for a particular disease (PD: in substantia nigra) (Heman-Ackah et al., [@B82]). For a disease like PD, due to blood brain barrier, miRNAs from the brain that are detectable in the serum or plasma samples may be very limited (Sheinerman and Umansky, [@B175]), hence may not reflect the miRNA expression in the tissue. Therefore, identification of these miRNAs for a purpose of marking each step of disease progression would therefore require more extensive and detailed studies.

It is also a huge challenge to pick the ultimate miRNAs as sensitive biomarkers for EOPD patients. Previous studies in EOPD patients (Table [1](#T1){ref-type="table"}) revealed that there were about 10 significantly expressed miRNAs in EOPD patients, yet their expression was similarly reduced in both EOPD and LOPD patients, except for miR-1, miR-22, and miR-331-5p. Even with that, miR-1 and miR-22 expressions were also found to be reduced in brain tissue (Liao et al., [@B117]) and in CSF (Gui et al., [@B71]) samples of LOPD patients, thus indicates that their expressions are also not specific enough for the detection of EOPD. Therefore, we have only one miRNA, miR-331-5p, in which its expression was increased in EOPD patients (Cardo et al., [@B24]). Focusing on the brain studies, there is one gene target of miR-331 which is the neuropilin 2 (NRP2) that is shown to promote the cell growth and proliferation of glioblastoma (Epis et al., [@B53]), yet the role of this gene in PD is unknown. Moreover, miR-331 was implicated in neuroprotection in ischemic cortex (Hunsberger et al., [@B85]) and therefore may suggest that this miRNA possess significant roles in PD but its function requires further study. The fact that its expression was increased in EOPD (Cardo et al., [@B24]) and never been implicated in LOPD studies, thus these findings imply that miR-331 has a strong potential as a biomarker for EOPD, though further information and studies are needed to validate its role and relationship in PD. Since the published EOPD studies was in lacking in numbers when compared to LOPD patients (Table [1](#T1){ref-type="table"}), there is a need to explore more miRNA profile in EOPD and compared to LOPD patients. Taken together of these findings in PD, it is clear that early events of PD progression, particularly in mitochondrial dysfunction, oxidative stress and neuroinflammation may hold the key genes and miRNAs for EOPD diagnosis. Furthermore, from the known mutations in PD, PRKN, PINK1, NFE2L2, A2M, and PARK7 genes (mitochondrial, oxidative genes and neuro-inflammation) (Krüger et al., [@B105]; Klein and Westenberger, [@B102]; Lin and Farrer, [@B119]; Todorovic et al., [@B196]) and other genes like DRD3 (Hassan et al., [@B78]) and HNMT (Yang X. et al., [@B220]) were showed to be associated with EOPD. Therefore, confirming the roles of these genes in early events of PD progression. So, further investigation are needed to allow for new identification of genes and their regulatory miRNAs thus consequently to find new biomarker for PD. It is also worth to mention that the miRNA-based research in PD is still in early exploring stages and not fully clear yet. Even though there are few discrepancies in the findings and its biological targets, some of these miRNAs showed potentials as biomarkers of EOPD, but the limitations in the amount of the previous published studies as well as the PD heterogeneity may therefore emphasize on the need for further investigations and research.

Conclusion {#s5}
==========

The characterization and differentiation of EOPD from LOPD may reveal important mechanisms for PD susceptibility and can help tailor the effective management of each subtype. As miRNAs are shown to regulate important genes such as *PRKN, PARK7, PINK1, SNCA*, and others genes in early event of PD progression, they could potentially be harnessed as biomarkers to diagnose EOPD and possibly to improve the management of PD. Although the idea of miRNA-based biomarkers is tempting, few limitations are needed to be considered. Majority of these miRNAs were found in LOPD studies, and the lack of the comparison to EOPD patients may undermine the actual progression marker by miRNA detection. Second, few of the significantly miRNAs were inconsistently expressed between samples types and studies and some of them were not consistently detected either. Therefore, by selecting the miRNAs in comparison of their targets/genes could provide further clarifications on their roles in diagnosing EOPD. Nevertheless, to what extent these miRNAs can be potentially used as biomarkers for early diagnosis for PD is unknown, and would therefore need extensive studies to characterize their regulatory and functional outcomes in differentiating subsets of PD.
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